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Abstract Blood sampling for newborn screening cannot be
standardized as for example blood collection in adults after
an overnight fast. Therefore the influence of postprandial
changes and individual variation is valuable information for
the assessment of sensitivity and specificity of newborn
screening for certain disorders. We have analyzed 92 pairs
of dried blood samples taken pre- and one hour postpran-
dially, respectively. We have determined the mean increase
in metabolite concentration and calculated its significance.
Individual variation after an overnight fast in healthy adults
(n=3) was between 12 and 32% (SD). Postprandial
increases of acylcarnitines were mostly not significant and
not exceeding 10%. Postprandial increase of amino acids
was highly significant for most proteinogenic amino acids,
but not for all. With the collected data we were able to
estimate that mainly decreased levels of methionine and, to
a lesser extent, of free carnitine could be “masked” by
postprandial increases of the respective metabolites, and
could therefore lead to false negative results for the
detection of disorders of cobalamin metabolism and
carnitine transporter deficiency.
Abbreviations
Newborn screening NBS
Inborn errors of metabolism IEM
Dried blood samples DBS
Thyroid stimulating hormone TSH
17α-hydroxyprogesterone 17-OHP
Medium-chain triglycerides MCT
Standard deviation SD
Introduction
Newborn screening (NBS) for inborn errors of metabolism
(IEM) and endocrinopathies is one of the most effective
tools of preventive health care. NBS is normally regionally
organized and ideally it should cover every newborn of the
respective population of that region. Special screening tests
in selected risk populations might be justified. However,
due to the ever-increasing worldwide mobility and interra-
cial marriages, these justifications will vanish over time. All
NBS programs normally use native capillary or venous
whole blood dried on special filter paper [the so-called
dried blood spots, or dried blood samples (DBS)] taken by
heal prick or venous puncture, respectively. The age at
sampling might differ from program to program, e.g.,
between 36 and 72 h in Germany and the 6th day of life
in England, and there are some differing recommendations
concerning early sampling for babies discharged early, as
well as the time of second sampling in preterms. These
differences, such as age at blood collection, birth weight, or
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gestational age, could be overcome by age, birth weight,
and gestational-age-related reference values. However, only
few publications on these data exist, and they often take
only the variation of a single variable into account
(Cavedon et al 2005, Meyburg et al 2001, Chace et al
2003, Honzík et al. 2005, Corte and Venta 2010, Duran
2008, Matern 2008). The influence of some medications,
such as dopamine and steroids upon thyroid-stimulating
hormone (TSH) (Wilber and Utiger 1969, Brabant et al.
1989, Haugen 2009) and 17α-hydroxyprogesterone (17-
OHP), respectively, is well known (Rohrer et al. 2003). For
children who need a blood transfusion, all screening
programs recommend that a first sample should be taken
before transfusion and a second sample 3–14 days after the
last transfusion. Nutrition is another factor that can
influence metabolite concentrations, in particular, substitu-
tion with carnitine, total parenteral nutrition, high caloric
glucose infusion (Shih 1984), and other food additives such
as medium-chain triglycerides (MCT), can influence the
concentrations of free carnitine, acylcarnitines, and amino
acids and might thereby cause false positive and false
negative screening results. In the normal clinical chemistry
setting, reference ranges for basal metabolite concentrations
are normally related to blood collections after an overnight
fast. Obviously, this strategy is impossible for newborns
and NBS. Therefore, NBS programs give no recommenda-
tions on the time of blood collection concerning the last
feed. Due to international ethical guidelines, it is impossible
to conduct studies in newborns and children to elucidate
these open questions. For this study, we had the opportunity
to reevaluate pairs of samples (DBS) from newborns that
were taken pre- and 1-h postprandially to prove or disprove
a portovenous shunt (DD: galactosemia) (Nishimura et al.
2004, Sodhi et al. 2007). With the data presented here, we
can estimate the variation of amino acids and acylcarnitines
due to the fed/fasted state. This will also give a rough
estimate of the bias that is included in all reference ranges
for amino acids and acylcarnitines in NBS programs.
Materials and methods
Blood was taken by heel prick or venous puncture and
spotted onto filter paper before and 1 h after feeding, either
in the course of follow-up tests after a positive newborn
screen for galactosemia in order to exclude or confirm a
portovenous shunt (n=80), or from healthy volunteers (n=
12; age 19–48 years). Newborns and volunteers were
healthy, on a normal diet and had no medications. None
of the newborns in the study had galactosemia or any kind
of liver disease. To determine individual variation of amino
acids and acylcarnitines in the fasted state, capillary blood
from three healthy volunteers was taken after an overnight
fast on 11, 13, and 15 consecutive days, respectively.
Amino acids and acylcarnitines were measured after
extraction with methanol, without derivatization, either
with the Neogram kit from Perkin Elmer, on an API2000
tandem mass spectrometer from SCIEX; or with the
Neobase kit from Perkin Elmer, on a TQD tandem mass
spectrometer from Waters. Measured acylcarnitines and
amino acids are listed in Table 1. For statistical analysis,
Table 1 List of acylcarnitines and amino acids measured from dried
blood spots (DBS)
acylcarnitines amino acids
free carnitine (C0) phenylalanine
acetylcarnitine (C2) tyrosine
propionylcarnitine (C3) methionine
butyrylcarnitine (C4) valine
isovalerylcarnitine (C5) leucine/isoleucine/
alloisoleucine/
hydroxyproline*
hexanoylcarnitine (C6) citrulline
octanoylcarnitine (C8) ornithine
decanoylcarnitine (C10) arginine
dodecanoylcarnitine (C12) alanine
tetradecanoylcarnitine (C14) glycine
palmitoylcarnitine (C16) proline
stearoylcarnitine (C18)
pentenoylcarnitine (C5:1)
octenoylcarnitine (C8:1)
decenoylcarnitine (C10:1)
decadienoylcarnitine (C10:2)
dodecenoylcarnitine (C12:1)
tetradecenoylcarnitine (C14:1)
tetradecadienoylcarnitine (C14:2)
hexadecenoylcarnitine (C16:1)
octadecenoylcarnitine (C18:1)
octadecadienoylcarnitine (C18:2)
malonylcarnitine (C3DC)/
hydroxybutyrylcarnitine (C4-OH) *
methylmalonylcarnitine (C4DC)/
hydroxyisovalerylcarnitine (C5-OH) *
glutarylcarnitine (C5DC)/
hydroxyhexanoylcarnitine (C6-OH) *
methylglutarylcarnitine (C6DC)
hydroxytetradecanoylcarnitine
(C14-OH)
hydroxyhexadecanoylcarnitine
(C16-OH)
hydroxyhexadecenoylcarnitine
(C16:1-OH)
hydroxyoctadecanoylcarnitine
(C18-OH)
hydroxyoctadecenoylcarnitine
(C18:1-OH)
*Isobaric compounds that cannot be distinguished by this method
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SPSS 16.0 was used. The t test for paired samples was used
to calculate the significance of pre/postprandial differences
of amino acid and acylcarnitine concentrations.
Results
The individual variation for free carnitine and acylcarnitines
is negligible [standard deviation (SD) range for free
carnitine 3.1–4.3 μmol/L; for acetylcarnitine 1.0–
2.5 μmol/L; for all other acylcarnitines <0.3 μmol/L]. The
individual variations for amino acids in the fasting state are
all between 12% and 32% (Table 2). The postprandial
increase was highly significant for most proteinogenic
amino acids; for acylcarnitines, with some exceptions, there
was no or no significant increase (see Table 3).
To estimate the influence of postprandial increases on
the recall rate for certain disorders, we calculated the centile
for the respective metabolites from 84,665 initial NBS
samples; day of sampling between 3 and 5 days. Since the
99.9th centile is a widely used cutoff in NBS programs, we
took the concentrations of the respective metabolites at the
99.9th centile, added and accordingly subtracted the mean
postprandial increase (pp-incr.) of the respective metabolite,
and determined the centiles for these concentrations (see
Fig. 1 for schematic description). These calculations give
the “cut-off –×% pp-incr.” and “cut-off +×% pp-incr.” and
the respective number of samples [(n–) and (n+)] within
these ranges for each metabolite, respectively. Since we
have no information on the fed/fasted state of the newborns,
we assume that there is an equal distribution of samples
taken from directly after feeding to samples taken shortly
before feeding. We then simplified this model by assuming
50% of the samples (n–) and (n+) were taken preprandially
and 50% postprandially, respectively. With this simplifica-
tion, we calculated the number of samples from the n–
group that would give a recall, if all samples would have
been taken postprandially [=> (r+)], and the number of
samples from the n+ group that would not give a recall, if
all samples would have been taken preprandially [=> (r-)].
The difference of these two numbers (r + minus r–) in
relation to the total number of recalls result in a factor (see
Table 3) that gives a rough estimate of the influence of
postprandial changes on the recall rate. A factor >1 would
argue in favor of a postprandial influence, a factor <1
would argue against it. For those analytes, where decreased
concentrations have pathological relevance (methionine,
free carnitine, octadecanoylcarnitine), we made the same
calculation also for the 0.1st centile.
Discussion
Since blood collection for NBS cannot be standardized like
blood collections in adults (normally drawn after an
overnight fast), and because intensive studies in children
are ethically not justifiable, all reference ranges generated
for NBS comprise a certain bias. Our results derived by a
model calculation can help to estimate the bias of amino
acid and acylcarnitine determination to a certain extent.
Amino acid and acylcarnitine concentrations may vary due
to many different conditions: age, birth weight (Fingerhut et
al. 2001), fed/fasted state, pre/postprandial time frame,
individual variation, total parenteral nutrition, carnitine
substitution. Some of these conditions can be controlled,
such as age and birth weight, by age- and birth-weight-
dependent reference ranges; others can be checked and
dealt with by ordering a second sample after a certain time
period (total parenteral nutrition, carnitine substitution).
Individual variation is inherently included in reference
ranges; however, the range of variation in a single
individual is often unknown. Finally, fed/fasted state or
pre/postprandial blood collection is uncontrollable in NBS.
The presented data show that mainly proteinogenic
amino acids have a highly significant postprandial increase,
which is, of course, not surprising; however, also ornithine,
a nonproteinogenic amino acid, shows significant increase.
From the acylcarnitines, only free carnitine, propionylcar-
nitine, and acylcarnitines associated to fat tissue (C18,
C18:1) showed modest but slightly significant increases.
The increase of propionylcarnitine might be explained by a
combination of dietary uptake and systemic increase due to
the increase in free carnitine. Increase of free carnitine
alone cannot be the explanation, since these two metabo-
lites are not consistently concurrently increased in the 84
sample pairs (data not shown).
However, for NBS, the increase in itself is not what is
important, but the influence on the recall rate, false positive,
and false negative results. To determine this influence, we
attempted to estimate the impact on recall rates as described
in the “Results” section and shown in Table 3 and Fig. 1.
compound SD (%)
phenylalanine (p) 13.2–20.6
tyrosine (p) 17.8–20.2
methionine (p) 19.0–24.9
valine (p) 16.7–18.5
leucine (p) 17.4–20.8
citrulline (n) 12.3–23.8
ornithine (n) 22.4–31.6
arginine (p) 18.5–22.6
alanine (p) 17.1–25.8
glycine (p) 16.6–23.9
proline (p) 13.6–19.7
Table 2 Individual variation of
amino acids in the fasted state
(range; n=3)
SD standard deviation, (p) pro-
teinogenic amino acid, (n) non-
proteinogenic amino acid
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Fatty acid oxidation disorders and organic acidurias, which
are detected through elevated concentrations of specific
acylcarnitines, should be mainly unaffected. Only screening
for propionic academia/methylmalonic acidemia might bear
a borderline risk of increased recall and false positive rates.
On the panel for NBS, so far, only two disorders are listed
that are detected through decreased levels of free carnitine
or specific acylcarnitines. Carnitine transporter (OCTN2)
deficiency with decreased free carnitine, and carnitine
palmitoyl transferase I deficiency (CPT-I) with decreased
levels of long-chain acylcarnitines (C16, C18). The
detection rate of OCTN2 deficiency is known to be not
Table 3 Mean postprandial increase of amino acids and acylcarnitines
compound postprandial increase (%) P value estimated influence on the recall rate (factor)
phenylalanine (p)*** 18 < 0.001 0.72
tyrosine (p)*** 14 < 0.001 0.18
methionine (p)*** 26 < 0.001 4.29 (increased) 1.84 (decreased)
valine (p)*** 18 < 0.001 1.62
leucinea (p)*** 25 < 0.001 5.19
proline (p)*** 11 < 0.001 0.46
arginine (p)*** 17 < 0.001 0.79
alanine (p)*** 11 < 0.001 0.44
ornithine (n)** 13 0.007 0.45
glycine (p)* 9 0.062 0.08
free carnitine (C0)* 6 0.016 0.09 (increased) 0.09 (decreased)
propionylcarnitine (C3)* 7 0.039 0.01
octadecanoylcarnitine (C18)* 7 0.048 0.25 (increased) 0.00 (decreased)
octadecenoylcarnitin (C18:1)* 4 0.019 0.10
citrulline (n) (n.s.) - 0.715 -
hexadecanoylcarnitine (C16) (n.s.) - 0.077 -
other acylcarnitines (n.s.) - 0.1–0.8 -
(p) proteinogenic amino acid, (n) nonproteinogenic amino acid, n.s. not significant (p>0.05)
*Significant ( p≤0.05) ;,**very significant ( p≤0.01) , ***highly significant (p≤0.001)
a Sum of isobaric amino acids (leucine + isoleucine + alloisoleucine + hydroxyproline)
b Sum of isobaric acylcarnitines (glutarylcarnitine + hydroxyhexanoylcarnitine)
Fig. 1 Model for estimating the influence of postprandial metabolite
changes: pp-incr. postprandial increase, cut-off –×% pp-incr. centile for
the concentration of the respective metabolite at the 99.9th centile minus
the percentage of respective postprandial increase, cut-off + ×% pp-incr.
centile for the concentration of the respective metabolite at the 99.9th
centile plus the percentage of respective postprandial increase, (n–)
number of samples within the concentration range for the respective
between the 99.9th centile and the centile corresponding to cut-off–×%
pp-incr., (n+) number of samples within the concentration range for the
respective between the 99.9th centile and the centile corresponding to
cut-off +×% pp-incr
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100% sensitive, which can be due to postprandial increase
of free carnitine; however, a more probable explanation
might be the different body stores of free carnitine, which
are dependent on the maternal levels of free carnitine
during pregnancy and lactation. The sensitivity for CPT-I
deficiency should not be influenced, since the most specific
metabolite ratio [C0/(C16 + C18)] (Fingerhut et al. 2001) is
more or less unaffected, because both denominator as well
as numerator will increase postprandially.
For amino acidemias and urea-cycle disorders, the
situation is more complex due to the greater number of
amino acids that are increased postprandially. Disorders that
might be affected are hyperphenylalaninemia (PKU/HPA),
homocystinuria, disorders of cobalamin metabolism, maple
syrup urine disease (MSUD), arginase deficiency, and
hyperornithinemia. Since homocystinuria, with methionine
as the marker metabolite, has an extremely low sensitivity
when NBS samples are taken during the first 4 days of life,
this can be neglected. The influence on PKU/HPA, MSUD,
arginase deficiency, and hyperornithinemia can also be
neglected, since postprandial increases are not specific, and
the interpretation of the whole amino acid profile with
slight increases of several amino acids can avoid unneces-
sary recalls. Only disorders of cobalamin metabolism,
which are detected by decreased levels of methionine, are
likely to give false negative results due to a possible
postprandial increase of methionine into the low normal
range. This is especially probable since methionine shows
the highest postprandial increase of all metabolites tested.
In conclusion, postprandial increases of amino acids and
acylcarnitines are partially significant and might be the
cause for some false positive screening results. However,
the danger for false negative results can only be suggested
for disorders of cobalamin metabolism and, to a lesser
extent, for OCTN2 deficiency, where decreased levels of
methionine and free carnitine, respectively, are the only
marker metabolites.
References
Brabant A, Brabant G, Schuermeyer T et al (1989) The role of
glucocorticoids in the regulation of thyrotropin. Acta Endocrinol
121:95–100
Cavedon CT, Bourdoux P, Mertens K et al (2005) Age related
variations in acylcarnitine and free carnitine concentrations
measured by tandem mass spectrometry. Clin Chem 51:745–752
Chace DH, Pons R, Chiriboga CA et al (2003) Normative data by
electrospray tandem mass spectrometry. Pediatr Res 53:823–829
Corte Z, Venta R (2010) Biological variation of free plasma amino
acids in healthy individuals. Clin Chem Lab Med 48:99–104
Duran M (2008) Amino Acids. In: Blau N, Duran M, Gibson KM
(eds) Laboratory Guide to the Methods in Biological Genetics.
Springer, Berlin-Heidelberg, pp 53–89
Fingerhut R, Röschinger W, Muntau AC et al (2001) Hepatic carnitine
palmitoyltransferase I deficiency: Acylcarnitine profiles in blood
spots are high specific. Clin Chem 47:1763–1768
Haugen BR (2009) Drugs that suppress TSH or cause central
hypothyroidism. Best Pract Res Clin Endocrinol Metab 23:793–
800
Honzík T, Chrastina P, Hansíková H et al (2005) Carnitine concen-
trations in term and preterm newborns at birth and during the first
days of life. Prague Med Rep 106:297–306
Matern D (2008) Acylcarnitines, including in vitro loading tests. In:
Blau N, Duran M, Gibson KM (eds) Laboratory Guide to the
Methods in Biological Genetics. Springer, Berlin-Heidelberg,
pp 171–206
Meyburg J, Schulze A, Kohlmueller D, Linderkamp O, Mayatepek E
(2001) Postnatal changes in neonatal acylcarnitine profile. Pediatr
Res 49:125–129
Nishimura Y, Tajima G, Dwi Bahagia A et al (2004) Differential
diagnosis of neonatal mild hypergalactosaemia detected by mass
screening: Clinical significance of portal vein imaging. J Inherit
Metab Dis 27:11–18
Rohrer TR, Gassmann KF, Pavel ME, Dörr HG (2003) Pitfall of
newborn screening for congenital adrenal hyperplasia due to 21-
hydroxylase deficiency. Biol Neonate 83:65–68
Shih VE (1984) Maple-Syrup-Urine Disease. N Engl J Med 310:596–
597
Sodhi KS, Thapa BR, Walia A, Khandelwal N (2007) Congenital
intrahepatic porto-systemic venous shunt with galactosemia.
Indian J Gastroenterol 26:87–88
Wilber JF, Utiger RD (1969) The effect of glucocorticoids on
thyrotropin secretion. J Clin Invest 48:2096–2103
J Inherit Metab Dis (2010) 33 (Suppl 2):S235–S239 S239
